2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
|Articles|October 12, 2006
AnorMED accepts Genzyme's Offer of US $13.50 a Share
Author(s)Pharmaceutical Technology Editors
Langley, BC, Canada (Oct. 10)-AnorMED Inc. has determined that Genzyme's US $580 million offer to acquire all outstanding AnorMED shares at US $13.50 a share is a "superior proposal."
Advertisement
Langley, BC, Canada (Oct. 10)-AnorMED Inc. (
Genzyme will amend its tender offer to increase the price offered from US $8.55 per share to US $13.50 per share and to extend the expiry date to November 1, 2006. Millennium has three business days to make adjustments to its own offer if the company still wishes to pursue purchase of the outstanding shares.
Advertisement
Related to this article
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Advertisement
Advertisement